Cargando…

Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice

Mice deficient for the cellular prion protein (PrP(C)) do not develop prion disease; accordingly, gene-based strategies to diminish PrP(C) expression are of interest. We synthesized a series of chemically modified antisense oligonucleotides (ASOs) targeted against mouse Prnp messenger RNA (mRNA) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nazor Friberg, Karah, Hung, Gene, Wancewicz, Ed, Giles, Kurt, Black, Chris, Freier, Sue, Bennett, Frank, DeArmond, Stephen J, Freyman, Yevgeniy, Lessard, Pierre, Ghaemmaghami, Sina, Prusiner, Stanley B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381600/ https://www.ncbi.nlm.nih.gov/pubmed/23344724 http://dx.doi.org/10.1038/mtna.2011.6

Ejemplares similares

Continuous Quinacrine Treatment Results in the Formation of Drug-Resistant Prions
por: Ghaemmaghami, Sina, et al.
Publicado: (2009)

Conserved properties of human and bovine prion strains on transmission to guinea pigs
por: Safar, Jiri G., et al.
Publicado: (2011)

Evidence That Bank Vole PrP Is a Universal Acceptor for Prions
por: Watts, Joel C., et al.
Publicado: (2014)

Resistance of Bovine Spongiform Encephalopathy (BSE) Prions to Inactivation
por: Giles, Kurt, et al.
Publicado: (2008)

Protease-Resistant Prions Selectively Decrease Shadoo Protein
por: Watts, Joel C., et al.
Publicado: (2011)

Pharmacokinetics of Quinacrine Efflux from Mouse Brain via the P-glycoprotein Efflux Transporter
por: Ahn, Misol, et al.
Publicado: (2012)

Antisense oligonucleotides extend survival of prion-infected mice
por: Raymond, Gregory J., et al.
Publicado: (2019)

Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides
por: Reidenbach, Andrew G., et al.
Publicado: (2019)

Asymptomatic deer excrete infectious prions in feces
por: Tamgüney, Gültekin, et al.
Publicado: (2009)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Protease-Sensitive Synthetic Prions
por: Colby, David W., et al.
Publicado: (2010)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

PrP(Sc )accumulation in neuronal plasma membranes links Notch-1 activation to dendritic degeneration in prion diseases
por: DeArmond, Stephen J, et al.
Publicado: (2010)

Trafficking of prion proteins through a caveolae-mediated endosomal pathway
por: Peters, Peter J., et al.
Publicado: (2003)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

Methionine oxidation within the prion protein
por: Bettinger, John, et al.
Publicado: (2020)

Convection-Enhanced Delivery of AAV2-PrPshRNA in Prion-Infected Mice
por: Ahn, Misol, et al.
Publicado: (2014)

Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency
por: Vickers, Timothy A., et al.
Publicado: (2014)

The Prion Disease Database: a comprehensive transcriptome resource for systems biology research in prion diseases
por: Gehlenborg, Nils, et al.
Publicado: (2009)

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
por: Scoles, Daniel R., et al.
Publicado: (2017)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
por: Qiao, Yuanyuan, et al.
Publicado: (2023)

Intracerebral administration of a modified antisense oligonucleotide targeting the dopamine system in a mouse model of Parkinson’s disease
por: Pavia-Collado, Rubén, et al.
Publicado: (2022)

Pharmacokinetics of quinacrine in the treatment of prion disease
por: Yung, Lotus, et al.
Publicado: (2004)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses
por: Spurgers, Kevin B., et al.
Publicado: (2008)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Successes and Challenges in Phenotype-Based Lead Discovery for Prion Diseases: Miniperspective
por: Ghaemmaghami, Sina, et al.
Publicado: (2014)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
por: Nishina, Tomoko, et al.
Publicado: (2015)

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish
por: Pauli, Andrea, et al.
Publicado: (2015)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016)

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s474siv3psujh422j9qk0qbn0q